Classifying Remission in Rheumatoid Arthritis Treat‐to‐Target Studies: Comment on the Article by Norvang Et Al

Wenhui Xie,Zhuoli Zhang
DOI: https://doi.org/10.1002/art.41269
2020-01-01
Abstract:We read with great interest the article by Norvang et al comparing achievement of remission in two different goal-oriented early rheumatoid arthritis (RA) cohorts [1]. In this study, the ACR/EULAR Boolean remission rates were significantly higher in ARCTIC than in NOR-VEAC cohort at 3 months, 12 months and 24 months, revealing that adherence to a more stringent definition of remission provided further potential for favorable outcomes. However, some issues should be addressed.
What problem does this paper attempt to address?